Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

被引：0
|
作者：
Francesco Spagnolo
Andrea Boutros
Federica Cecchi
Elena Croce
Enrica Teresa Tanda
Paola Queirolo
机构：
[1] IRCCS Ospedale Policlinico San Martino,Medical Oncology 2
[2] European Institute of Oncology (IEO),Melanoma, Sarcoma & Rare Tumors Division
来源：
BMC Cancer | / 21卷
关键词：
Melanoma; Immunotherapy; Immune-related response criteria; Treatment beyond progression; Anti-PD-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Yuegang Li
    Yuwei Du
    Chi Xue
    Pei Wu
    Nan Du
    Guolian Zhu
    Huimian Xu
    Zhi Zhu
    BMC Gastroenterology, 22
  • [42] Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
    Li, Yuegang
    Du, Yuwei
    Xue, Chi
    Wu, Pei
    Du, Nan
    Zhu, Guolian
    Xu, Huimian
    Zhu, Zhi
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [43] The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis
    Zhang, Tengfei
    Fan, Ruitai
    Shi, Ni
    Ma, Wang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    Champiat, Stephane
    Dercle, Laurent
    Ammari, Samy
    Massard, Christophe
    Hollebecque, Antoine
    Postel-Vinay, Sophie
    Chaput, Nathalie
    Eggermont, Alexander
    Marabelle, Aurelien
    Soria, Jean-Charles
    Ferte, Charles
    CLINICAL CANCER RESEARCH, 2017, 23 (08) : 1920 - 1928
  • [45] Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis
    Habibi, Mohammad Amin
    Mirjani, Mohammad Sina
    Ahmadvand, Muhammad Hussain
    Delbari, Pouria
    Eftekhar, Mohammad Shahir
    Ghazizadeh, Yalda
    Ghezel, Mohammad Amin
    Rad, Romina Hamidi
    Vakili, Kimia Ghazi
    Lotfi, Sohrab
    Minaee, Poriya
    Eazi, Seyedmohammad
    Mehrizi, Mohammad Ali Abouei
    Ahmadpour, Sajjad
    NEUROSURGICAL REVIEW, 2024, 47 (01)
  • [46] Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis
    Nie, Run-Cong
    Duan, Shu-Qiang YuanJin-Ling
    Liang, Yao
    Chen, Xiao-Jiang
    Chen, Yong-Ming
    Luo, Tian-Qi
    Chen, Guo-Ming
    Wang, Yun
    Li, Yuan-Fang
    IMMUNOTHERAPY, 2020, 12 (18) : 1313 - 1324
  • [47] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [48] Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
    Aya, Francisco
    Gaba, Lydia
    Victoria, Ivan
    Fernandez-Martinez, Aranzazu
    Tosca, Monica
    Prat, Aleix
    Arance, Ana
    FUTURE ONCOLOGY, 2016, 12 (23) : 2683 - 2688
  • [49] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato
    Noriyuki Okonogi
    Takashi Nakano
    International Journal of Clinical Oncology, 2020, 25 : 801 - 809
  • [50] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Sato, Hiro
    Okonogi, Noriyuki
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 801 - 809
12345